申请人:NISSAN CHEMICAL INDUSTRIES LTD.
公开号:EP0655455A1
公开(公告)日:1995-05-31
A pyridine compound of a formula I:
wherein Ar¹ is phenyl, pyridyl, furyl or 2,1,3-benzoxadiazol-4-yl, which maybe substituted by one or two substituents selected from the group consisting of NO₂, CF₃, Br, Cl, F, R⁶ (wherein R⁶ is C₁-C₄ alkyl), OH, OR⁶, OCHF₂, COOR⁶, NH₂, NHR⁶, NR⁶R⁷ (wherein R⁷ has the same meaning as R⁶), CONH₂, CONHR⁶, CONR⁶R⁷, COSR⁶, SR⁶, S(O)R⁶, S(O)₂R⁶, SO₃H, SO₃R⁶, SO₂NH₂, SO₂NHR⁶, SO₂NR⁶R⁷, CN and phenyloxy;
the nitrogen-containing hetero ring portion represents a 1,4-dihydropyridine ring or a pyridine ring;
Z is a group of the formula II:
wherein each of R⁴ and R⁵ which may be the same or different is OH, C₁-C₁₂ linear or branched primary or secondary alkyloxy, C₃-C₆ linear or branched unsaturated alkyloxy, C₃-C₆ cycloalkyloxy, C₁-C₆ alkyloxy substituted by C₃-C₆ cycloalkyl, OAr² (wherein Ar² is phenyl which may be substituted by halogen, C₁-C₃ alkyl or C₁- C₃ alkyloxy), OANR⁶R⁷ (wherein A is C₂-C₆ alkylene, which may be substituted by C₁-C₃ alkyl or Ar²), OAN(CH₂Ar²)R⁶, OAOR⁶, OACN, NH₂, NHR⁶, NR⁶R⁷, 1-piperidinyl or 1-pyrrolidinyl, or R⁴ and R⁵ together form OYO (wherein Y is C₂-C₄ linear saturated or unsaturated alkylene which may substituted by R⁶, CO₂R⁶, OR⁶, or A), NHYO, R⁶NYO, NHYNH, R⁶NYNH or R⁶NYNR⁷;
R¹ is present only when the nitrogen-containing hetero ring is a 1,4-dihydropyridine ring, and it is AN(CH₂CH₂)₂O;
R² is R⁶, Ar², Ar²CH=CH, Ar²CH(OH)CH₂, CHO, CN, CH₂OH, CH₂OR⁶, CH₂CH₂N(CH₂CH₂)₂NR⁶, NH₂, NHR⁶ or NR⁶R⁷;
R³ is hydrogen, C₁-C₁₂ linear or branched alkyl, C₃-C₆ linear or branched unsaturated alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkyl substituted by C₃-C₆ cycloalkyl, AOR⁶, AO(CH₂)mAr² (wherein m is an integer of from 0 to 3) , (CH₂)mAr², ANH₂, ANHR⁶, ANR⁶R⁷, ANR⁶(CH₂)mAr², AN (CH₂)mAr²} (CH₂)nAr³} (wherein n has the same meaning as m, and Ar³ has the same meaning as Ar²), 1-benzyl-4-piperidinyl, 1-benzyl-2-piperidinyl, 2-pyridinylnethyl, 3-pyridinylmethyl, AQ (wherein Q is pyrrolidine or piperidine which may be substituted by (CH₂)mAr²), 4-R⁶-1-piperazinyl, 4-Ar²-1-piperazinyl, 4-(Ar²)₂CH-1-piperazinyl or 4-(Ar²)₂CH-1-(1,4-diazacycloheptyl);
or a pharmaceutically acceptable salt of the compound.
式 I 的吡啶化合物:
其中 Ar¹ 为苯基、吡啶基、呋喃基或 2,1,3-苯并噁二唑-4-基,可被一个或两个选自以下组别的取代基取代:NO₂、CF₃、Br、Cl、F、R⁶(其中 R⁶ 为 C₁-C₄烷基)、OH、OR⁶、OCHF₂、COOR⁶、NH₂、NHR⁶、NR⁶R⁷ (其中 R⁷ 的含义与 R⁶ 相同)、CONH₂、CONHR⁶、CONR⁶R⁷、COSR⁶、SR⁶、S(O)R⁶、S(O)₂R⁶、SO₃R⁶、SO₃H₂、SO₂NHR⁶、SO₂NR⁶R⁷、CN 和苯氧基;
含氮杂环部分代表 1,4-二氢吡啶环或吡啶环;
Z 是式 II 的基团:
其中可能相同或不同的 R⁴ 和 R⁵ 均为 OH、C₁-C₁₂ 直链或支链伯或仲烷氧基、C₃-C₆ 直链或支链不饱和烷氧基、C₃-C₆ 环烷氧基、被 C₃-C₆ 环烷基取代的 C₁-C₆ 烷氧基、OAr²(其中 Ar² 为苯基,可被卤素、C₁-C₃ 烷基或 C₁- C₃ 烷氧基取代)、OANR⁶(其中 A 为 C₂-C₆亚烷基,可被 C₁-C₃ 烷基或 Ar² 取代)、OAN(CH₂Ar²)R⁶、OAOR⁶、OACN、NH₂、NHR⁶、NR⁶R⁷、1-哌啶基或 1-吡咯烷基、或 R⁴ 和 R⁵ 共同形成 OYO(其中 Y 为 C₂-C₄ 直链饱和或不饱和亚烷基,可被 R⁶、CO₂R⁶、OR⁶ 或 A 取代)、NHYO、R⁶NYO、NHYNH、R⁶NYNH 或 R⁶NYNR⁷;
R¹ 仅存在于含氮杂环为 1,4-二氢吡啶环时,且为 AN(CH₂CH₂)₂O ;
R² 是 R⁶、Ar²、Ar²CH=CH、Ar²CH(OH)CH₂、CHO、CN、CH₂OH、CH₂OR⁶、CH₂CH₂N(CH₂CH₂)₂NR⁶、NH₂、NHR⁶ 或 NR⁷;
R³ 是氢、C₁-C₁₂ 直链或支链烷基、C₃-C₆ 直链或支链不饱和烷基、C₃-C₆ 环烷基、被 C₃-C₆ 环烷基取代的 C₁-C₆ 烷基、AOR⁶、AO(CH₂)mAr²(其中 m 为 0 至 3 的整数)、(CH₂)mAr²、ANH₂、ANHR⁶、ANR⁶R⁷、ANR⁶(CH₂)mAr²、AN (CH₂)mAr²}(CH₂)nAr³}(其中 n 与 m 意义相同,Ar³ 与 Ar² 意义相同)、1-苄基-4-哌啶基、1-苄基-2-哌啶基、2-吡啶基甲基、3-吡啶基甲基、4-R⁶-1-哌嗪基、4-Ar²-1-哌嗪基、4-(Ar²)₂CH-1-哌嗪基或 4-(Ar²)₂CH-1-(1,4-二氮杂环庚基);
或该化合物的药学上可接受的盐。